{"groups":[{"description":"160 milligram (mg) Selpercatinib administered orally, twice daily (BID) continuously in 21-day cycles.","id":"FG000","title":"Selpercatinib (TRT A)"},{"description":"Pemetrexed 500 milligrams per meter squared (mg/m2) administered intravenously (IV) on Day 1, every 3 weeks (Q3W), plus investigator's choice of carboplatin area under the concentration versus time curve 5 (AUC 5 \\[maximum dose 750 mg\\]) IV, or cisplatin 75mg/m2 IV on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.","id":"FG001","title":"Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"93"},{"groupId":"FG001","numSubjects":"30"}],"type":"On Treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"159"},{"groupId":"FG001","numSubjects":"102"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"158"},{"groupId":"FG001","numSubjects":"98"}],"type":"Received at Least One Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"61"},{"groupId":"FG001","numSubjects":"70"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"98"},{"groupId":"FG001","numSubjects":"32"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"If a participant has a recorded death on study, or is alive and being followed but off treatment, then the participant can be considered to be study completer."}